Skip to main content
Retour
Watch Compare

Aquestive Therapeutics, Inc.

Qualité des données : 100%
AQST
NASDAQ Manufacturing Chemicals
4,20 €
▲ 0,01 € (0,12%)
Cap. Boursière: 508,32 M
6 months return
—
Momentum
Neutral
5Y revenue growth
-3,25%

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -3,25% annually over 5 years
Negative free cash flow of -52,99 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 19,36%
Capital efficient — spends only 1,26% of revenue on capex

Price History

Croissance

Revenue Growth (5Y)
-3,25%
En dessous de la moyenne du secteur (1,72%)
Revenue (1Y)-22,61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-53,83%
Net Margin-188,09%
Op. Margin-159,50%

Sécurité

Debt / Equity
N/A
Current Ratio5,93
Interest Coverage-6,39

Valorisation

PE (TTM|NTM)
-6,07 | -7,03
En dessous de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E -6,1 -1,5
P/B — 1,6
ROE % — -54,4
Net Margin % -188,1 -41,5
Rev Growth 5Y % -3,3 1,7
D/E — 0,3

Objectif de Cours des Analystes

9 analystes

Consensus des analystes : objectif moyen vs prix actuel et notation.

Buy
Actuel
4,20 €
+111.9%
Objectif
8,89 €
6,00 €
9,00 €
11,00 €
Prévisions
P/E Prévisionnel -7,03
BPA Prévisionnel -0,58 €
CA Est. 71,85 M

Estimations de Bénéfices

Prévisions d’EPS et de chiffre d’affaires par période. Annuel = exercices ; trimestriel = prochains trimestres.

Période BPA Est. CA Est. Analystes
FY2027 -0,58 €
-0,75 € – -0,41 €
71,85 M 2
FY2026 -0,46 €
-0,55 € – -0,37 €
48,07 M 2

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,12 € -0,14 € -18,1%
Q32025 -0,11 € -0,11 € -4,2%
Q22025 -0,17 € -0,12 € +32,3%
Q12025 -0,16 € -0,22 € -39,7%

ETFs Holding This Stock

BRSIX BRSIX
0,47% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0,03% weight
IIRSX IIRSX
0,02% weight
IRSIX IRSIX
0,02% weight
IRCIX IRCIX
0,02% weight
VVICX VVICX
0,02% weight
IRSSX IRSSX
0,02% weight
IWV logo IWV iShares Russell 3000 ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -22,61% Revenue Growth (3Y) -6,16%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -3,25% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 44,55 M Net Income (TTM) -83,78 M
ROE N/A ROA -65,14%
Gross Margin N/A Operating Margin -159,50%
Net Margin -188,09% Free Cash Flow (TTM) -52,99 M
ROIC -53,83% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,93
Interest Coverage -6,39 Asset Turnover 0,35
Working Capital 126,10 M Tangible Book Value -4,11 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6,07 Forward P/E -7,03
P/B Ratio N/A P/S Ratio 11,41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 7,07 Fwd Earnings Yield N/A
FCF Yield -10,43%
Market Cap 508,32 M Enterprise Value 424,25 M
Per Share
EPS (Diluted TTM) -0,78 Revenue / Share 0,37
FCF / Share -0,43 OCF / Share -0,43
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,26% FCF Conversion 63,25%
SBC-Adj. FCF -60,82 M Growth Momentum -19,36

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 44,55 M 57,56 M 50,58 M 47,68 M 50,83 M
Net Income -83,78 M -44,14 M -7,87 M -54,41 M -70,54 M
EPS (Diluted) -0,78 -0,51 -0,13 -1,12 -1,85
Gross Profit — — — — —
Operating Income -71,05 M -30,77 M -15,10 M -42,07 M -34,68 M
EBITDA — — — — —
R&D Expenses 17,19 M 20,28 M 13,10 M 17,48 M 17,05 M
SG&A Expenses 79,85 M 50,18 M 31,75 M 52,88 M 53,48 M
D&A 548 000,0 718 000,0 1,35 M 2,39 M 2,96 M
Interest Expense 11,12 M 11,12 M 6,34 M 6,55 M 10,05 M
Income Tax 0,0 -14 000,0 245 000,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 160,43 M 101,42 M 57,42 M 57,07 M 61,99 M
Total Liabilities 194,09 M 161,58 M 163,91 M 175,62 M 144,13 M
Shareholders' Equity -33,66 M -60,16 M -106,49 M -118,55 M -82,13 M
Total Debt 45,00 M 45,00 M 45,00 M — —
Cash & Equivalents — — — — —
Current Assets 149,27 M 88,22 M 40,97 M 39,89 M 47,26 M
Current Liabilities 47,61 M 18,87 M 18,31 M 39,53 M 21,96 M